Tryptophan-Kynurenine Pathway Metabolism in the Pathophysiology of Cognitive Impairment in Schizophrenia.

Plain-language summary

This study examines the role of the tryptophan-kynurenine metabolic pathway in the mechanisms underlying cognitive impairment seen in schizophrenia. Healthy volunteers without any psychiatric disorder, matched to the patient group by sex, age, and education level, may take part. This is a study without a clinical phase and is enrolling participants by invitation.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Enrolling by invitation

Sponsor

Tianjin Anding Hospital

Start date

2/19/2024

Estimated completion

6/30/2026

Countries

China

Related genes

Locations

• Tianjin, China

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Healthy volunteers matched to the patient group on sex, age, and education level;
* Ethnic Han Chinese;
* Able and willing to provide written informed consent.

Exclusion Criteria:

* Significant comorbid medical or neurological conditions;
* Any DSM-5-defined psychiatric disorder;
* Family history of psychiatric illness spanning three or more generations;
* Current use of psychoactive medications;
* Refusal to provide informed consent/participate.